Eidelman Virant Capital’s Harte-Hanks HHS Stock Holding History

Eidelman Virant Capital’s Portfolio HHS Stock Details HHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$805K	Sell	70,500 -55,000	-44%	-$733K	0.59%	48
2022 Q2	$1.44M	Sell	125,500 -90,500	-42%	-$792K	1.04%	29
2022 Q1	$1.64M	Hold	216,000	–	–	0.88%	31
2021 Q4	$1.65M	Sell	216,000 -31,000	-13%	-$246K	0.6%	46
2021 Q3	$1.93M	Sell	247,000 -53,175	-18%	-$415K	0.74%	40
2021 Q2	$1.74M	Sell	300,175 -124,313	-29%	-$721K	0.67%	43
2021 Q1	$1.87M	Buy	424,488 +98,488	+30%	+$433K	0.75%	44
2020 Q4	$897K	Buy	326,000 +121,000	+59%	+$333K	0.39%	56
2020 Q3	$426K	Buy	205,000 +57,000	+39%	+$163K	0.23%	82
2020 Q2	$450K	Sell	148,000 -69,817	-32%	-$165K	0.32%	67
2020 Q1	$342K	Sell	217,817 -37,583	-15%	-$112K	0.36%	67
2019 Q4	$914K	Buy	255,400 +17,500	+7%	+$52K	0.45%	68
2019 Q3	$726K	Sell	237,900 -400	-0.2%	-$1.26K	0.42%	64
2019 Q2	$524K	Buy	238,300 +24,000	+11%	+$76.2K	0.28%	77
2019 Q1	$765K	Buy	214,300 +7,000	+3%	+$24.4K	0.54%	61
2018 Q4	$502K	Sell	207,300 -17,602	-8%	-$83.9K	0.38%	73
2018 Q3	$1.6M	Buy	224,902 +17,200	+8%	+$151K	0.79%	42
2018 Q2	$2.31M	Sell	207,702 -1,080	-0.5%	-$11K	1.42%	25
2018 Q1	$1.91M	Sell	208,782 -1,500	-0.7%	-$13.7K	1.25%	26
2017 Q4	$1.99M	Sell	210,282 -19,728	-9%	-$199K	1.17%	29
2017 Q3	$2.46M	Sell	230,010 -10,150	-4%	-$93.4K	1.46%	22
2017 Q2	$2.47M	Sell	240,160 -97,425	-29%	-$1.23M	1.43%	23
2017 Q1	$4.73M	Sell	337,585 -20,075	-6%	-$306K	3.26%	5
2016 Q4	$5.4M	Buy	357,660 +26,695	+8%	+$404K	3.09%	5
2016 Q3	$5.36M	Buy	330,965 +60,559	+22%	+$998K	3.3%	5
2016 Q2	$4.3M	Buy	270,406 +236,806	+705%	+$4.18M	2.64%	6
2016 Q1	$867K	Buy	33,600 +8,800	+35%	+$270K	0.59%	55
2015 Q4	$803K	Buy	24,800 +15,100	+156%	+$565K	0.48%	69
2015 Q3	$342K	Sell	9,700 -4,608	-32%	-$208K	0.23%	92
2015 Q2	$853K	Buy	14,308 +8,908	+165%	+$599K	0.38%	73
2015 Q1	$421K	Buy	5,400 +3,000	+125%	+$232K	0.18%	101
2014 Q4	$186K	Sell	2,400 -9,100	-79%	-$595K	0.08%	141
2014 Q3	$733K	Buy	11,500 +2,500	+28%	+$170K	0.35%	63
2014 Q2	$647K	Buy	9,000 +4,000	+80%	+$309K	0.27%	81
2014 Q1	$442K	Buy	+5,000	New	+$389K	0.2%	90

Other funds holding HHS

WCM

Westerly Capital Management San Francisco, California $368M AUM 42.67% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Eidelman Virant Capital's HHS Position: Q3 2022 in Review

Eidelman Virant Capital reduced its Harte-Hanks (HHS) stake by 44% in Q3 2022, selling an estimated $733K and leaving 70,500 shares worth $805K. The position accounts for 0.59% of the portfolio, ranked #48.

Eidelman Virant Capital first reported a position in HHS in Q1 2014 and has held it in 35 quarters since. The position peaked at $5.4M in Q4 2016. 37 funds tracked by Wall St. Rank hold HHS as of Q3 2022.

Eidelman Virant Capital held 70,500 shares of Harte-Hanks worth $805K as of Q3 2022.
Eidelman Virant Capital sold 55,000 Harte-Hanks shares in Q3 2022, an estimated $733K.
Harte-Hanks made up 0.59% of Eidelman Virant Capital's portfolio in Q3 2022, its #48 holding.
Eidelman Virant Capital first reported a position in Harte-Hanks in Q1 2014 and has held it in 35 quarters since.
Eidelman Virant Capital's Harte-Hanks position peaked at $5.4M in Q4 2016.
37 funds tracked by Wall St. Rank held Harte-Hanks as of Q3 2022.

Based on Eidelman Virant Capital's 13F filing for Q3 2022, filed 25 Oct 2022.